ly-146032 and Diarrhea

ly-146032 has been researched along with Diarrhea* in 1 studies

Other Studies

1 other study(ies) available for ly-146032 and Diarrhea

Article	Year
Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea. Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12 Novel cyclic lipopeptides with different acyl tails were synthesized via a semisynthetic approach. Structure-activity relationship studies revealed that lipophilicity, chain length, and the location of key aromatic functionalities of the tail modulated activity. The lead compound surotomycin exhibited significantly improved in vitro activity compared with daptomycin (MIC90 0.5 vs 2 μg/mL) against Clostridium difficile including NAP1 epidemic strains. In hamster efficacy studies, surotomycin protected animals at a dose of 0.5 mg/kg, PO. Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Cricetinae; Diarrhea; Enterocolitis, Pseudomembranous; Lipopeptides; Male; Microbial Sensitivity Tests; Peptides, Cyclic; Structure-Activity Relationship	2015

Article

Year

Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.

Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12

Novel cyclic lipopeptides with different acyl tails were synthesized via a semisynthetic approach. Structure-activity relationship studies revealed that lipophilicity, chain length, and the location of key aromatic functionalities of the tail modulated activity. The lead compound surotomycin exhibited significantly improved in vitro activity compared with daptomycin (MIC90 0.5 vs 2 μg/mL) against Clostridium difficile including NAP1 epidemic strains. In hamster efficacy studies, surotomycin protected animals at a dose of 0.5 mg/kg, PO.

Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Cricetinae; Diarrhea; Enterocolitis, Pseudomembranous; Lipopeptides; Male; Microbial Sensitivity Tests; Peptides, Cyclic; Structure-Activity Relationship

2015